{"success":true,"data":{"pressRelease":{"id":"160940","rtpr_id":"nGNXF0XkC-20261005","ticker":"ABBV","exchange":"NYSE","all_tickers":["ABBV","GMAB"],"title":"Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma","author":"Globe Newswire","published_at":"2026-10-05T18:49:00.394Z","article_body":"Company Announcement\n\nCOPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026\n* EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody\ncombination therapy to demonstrate statistically significant and clinically\nmeaningful improvement in progression-free survival (PFS) in frontline\ndiagnosed diffuse large B-cell lymphoma (DLBCL) patients\n* Based on the topline results, Genmab and AbbVie will engage global\nregulatory authorities\nGenmab A/S\n(https://www.globenewswire.com/Tracker?data=AW_Zl3lIf25cNfe3iJ8zMZWSi_BbFABsZPNhliWJir05MQuPFrgG4te4ZY8qu8lbDcwo4knvO5oH8Xjv5rC5BQ==)\n(Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline\nresults from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment\nduration epcoritamab, a T-cell engaging bispecific antibody administered\nsubcutaneously, in combination with standard of care rituximab,\ncyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone\n(R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse\nlarge B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI)\nscore of 2 to 5. The trial demonstrated a statistically significant and\nclinically meaningful improvement in progression-free survival (PFS) in DLBCL\npatients with an IPI score of 2 to 5. The risk of disease progression or death\nwas reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001). The safety\nprofile of epcoritamab when administered in combination with standard of care\nR-CHOP was generally well tolerated and consistent with the previously\nreported safety profiles of the individual agents (epcoritamab and R-CHOP).\n\n“These topline results of epcoritamab in combination with R-CHOP mark the\nfirst Phase 3 study to demonstrate a statistically significant improvement in\nprogression-free survival in patients with newly diagnosed DLBCL treated with\na bispecific antibody combination and have the potential to reshape the\nfrontline treatment landscape,” said Jan van de Winkel, Ph.D., Chief\nExecutive Officer of Genmab. “While treatment advances have improved\noutcomes for patients with diffuse large B-cell lymphoma, options for newly\ndiagnosed patients remain limited, reinforcing the need for additional\ntherapies that can treat as many patients as possible in the frontline\nsetting.”\n\n“DLBCL is an aggressive disease and the need to advance treatment options is\ncritical. These positive topline results suggest that epcoritamab combined\nwith R-CHOP could offer a potential new standard of care in newly diagnosed\nDLBCL patients,” said Daejin Abidoye, MD, vice president, therapeutic area\nhead, oncology, solid tumor and hematology, AbbVie. “The findings further\nstrengthen our understanding and potential of bispecifics across the lymphoma\ntreatment landscape, as we work to address urgent needs in this patient\npopulation.”\n\n\"As an investigator with firsthand experience in both the landmark trial that\nestablished R-CHOP as a standard of care nearly 25 years ago and EPCORE\nDLBCL-2, it is particularly meaningful to see the potential benefit of\nbispecific antibody therapy in newly diagnosed diffuse large B-cell\nlymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service and\nholder of the Steven A. Greenberg Chair at Memorial Sloan Kettering Cancer\nCenter. “The 51% reduction in the risk of progression or death is clinically\nmeaningful and highly relevant to everyday practice. These results have the\npotential to be practice-changing and could mark an important step forward in\nbringing the opportunity of cure to more patients.”\n\nData will be submitted for presentation at a future medical meeting. Genmab\nand AbbVie will engage global regulatory authorities to determine next steps.\nEpcoritamab plus R-CHOP is an investigational combination not approved by\nregulatory authorities.\n\nAbout the EPCORE(®) DLBCL-2 Trial \nEPCORE DLBCL-2 (NCT05578976\n(https://www.globenewswire.com/Tracker?data=fg7FxrXGTAGQushK-9dazm9KG23BceQnBEROsaliGfdWVkaDk_3jHfDf72gxFa8RXZGzKUHcyWxFRQtaTG19BLImWFfsY2aWNm0Vmq0bBOV5EwTKNb9xu7Tg3u4I_Ol2Jk8OsjadoesmoFtYZnk7Zca-gzPL8x_5p-l_nvooBrlwY5F81NzQzCwnNC5XxHm5A1oL_ZCaw6M2z98YUpTEq0nkrhBhCdjA9Fxg5EQrLXKKepIRoaP5BgbDLiHMZz7q-rvqcW-ncvCDKKtJJMdX4LOPKhjNUhbBerrH--K4-w1cUGPwxy9PUjwyO7D6aeqfy5EqBG_-X5hPunsY6cXXoE2OFnkEYBn-iOYlX7_1Qd6daoso6cOm_rHR4eYxgxMyr3R0IG4fvSAbJHomxk-ieQ4ahsVMTFso6_dfE5egg8BbqwoXuPb5DKngXxEnUqBF27pcFeixkwnbKopyatT04FfN7asbYXirYWKEwNGixlAAHJ4O0F4vdwsco4bGD1uebmdUmSGOWXidnizzi1U_hYGAFzlLfTbXVJXJ1CuW1zxr87Wl3t7C-lfNMhRjYoS-nvWL77ZbQHElefPJjXO7u62oPdLrTKvq-GeW-YeqhAk31O_ePyraEIdO1Zgw5AgLFVEaEplNARqpDrP3EZvhXg==))\nis a global Phase 3 open label, multi-center, randomized trial to evaluate the\nefficacy of fixed duration, subcutaneous epcoritamab (GEN3013,\nDuoBody(®)-CD3xCD20) and standard of care rituximab, cyclophosphamide,\ndoxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) compared to\nR-CHOP alone in patients with newly diagnosed large B-cell lymphoma (DLBCL).\nThe trial enrolled subjects with an International Prognostic Index (IPI) score\nof 2 to 5, including patients with diffuse large B-cell lymphoma, not\notherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC\nand BCL2 and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B),\nT-cell/histiocyte-rich large B-Cell lymphoma (TCHR LBLC), and Epstein-Barr\nVirus-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The primary\nendpoint is PFS in participants with an International Prognostic Index (IPI)\nof 3-5 and the key secondary endpoint is PFS in total participants (IPI score\nof 2-5). The risk of disease progression or death for the primary endpoint\npopulation was reduced by 51% (HR 0.49 [95% CI 0.35, 0.69]; p-value < 0.0001).\nPatients were randomized 2:1 to receive a fixed-duration regimen of\nepcoritamab plus R-CHOP for six cycles followed by epcoritamab alone for two\ncycles, or R-CHOP for six cycles followed by rituximab for two cycles. The\ntrial started on February 8, 2023, and is ongoing.\n\nMore information on this trial can be found at\nhttps://clinicaltrials.gov/study/NCT05578976 (NCT: NCT05578976).\n\nAbout Diffuse Large B-Cell Lymphoma\nDiffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of\nnon-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30\npercent of all NHL cases.(i)(,)(ii) In the U.S., there are approximately\n25,000 new cases of DLBCL diagnosed each year.(iii) DLBCL can arise in lymph\nnodes as well as in organs outside of the lymphatic system, occurs more\ncommonly in the elderly and is slightly more prevalent in men.(iv)(,)(v) DLBCL\nis a fast-growing type of NHL, a cancer that develops in the lymphatic system\nand affects B-cell lymphocytes, a type of white blood cell. For many people\nliving with DLBCL, their cancer either relapses, which means it may return\nafter treatment, or becomes refractory, meaning it does not respond to\ntreatment. Although new therapies have become available, treatment management\ncan remain a challenge.(iv)(,)(vi)\n\nAbout Epcoritamab \nEpcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary\nDuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3\ntechnology is designed to direct cytotoxic T cells selectively to elicit an\nimmune response toward target cell types. Epcoritamab is designed to\nsimultaneously bind to CD3 on T cells and CD20 on B cells and induces\nT-cell-mediated killing of CD20+ cells.(vii)\n\nEpcoritamab (approved under the brand name EPKINLY(®) in the U.S. and Japan,\nand TEPKINLY(®) in the EU) has received regulatory approval in certain\nlymphoma indications in more than 65 countries. Where approved, epcoritamab is\na readily accessible therapy. Epcoritamab is being co-developed by Genmab and\nAbbVie as part of the companies' oncology collaboration. The companies share\ncommercial responsibilities in the U.S. and Japan, with AbbVie responsible for\nfurther global commercialization. Both companies will pursue additional\ninternational regulatory approvals for the relapsed or refractory (R/R)\nfollicular lymphoma (FL) indication and additional approvals for the R/R\ndiffuse large B-cell lymphoma (DLBCL) indication. \n\nGenmab and AbbVie continue to evaluate the use of epcoritamab as a\nmonotherapy, and in combination, across lines of therapy in a range of\nhematologic malignancies. This includes a trial evaluating epcoritamab in\ncombination with lenalidomide and rituximab (R(2)) compared to\nchemoimmunotherapy in patients with previously untreated FL (NCT06191744\n(https://www.globenewswire.com/Tracker?data=fg7FxrXGTAGQushK-9dazmobqaLl-UqO2MdV9cKJ9ipMYRN9vINLeOASahrbnVt5_AMVaEpdyFf_Tf6Hr6o_j1GmATokaqHcwuETgd3cpG1m7yhcqcHxHFNTIqUNA__AD4fkb-2vWrSCFWcwWa2YFukUnrPJ_PPZjFxxGDRjkNdSnk_pAA7JLhhyNWRrYyLRFjOacgRAPsk5Ffta0hJ6qHXeN6BYSVDijvHaN_bqhY5o9ENXEqbZsh7tHUZU1jqSW4TBOlq1WxWCRyJ3Wa2UTUYfaJH-kBc36yaoW-cd18CT5xbN6RzCoMgGQvcun0OW4U_cQJkn_-VRwWJwcsUL6FidReum-3W5BaIE4QutTubWsoQ8eQ-fOdfeC-deIGw_EqREP4R1ocbPLDyd5xrArnB_xIIN-rHwcWt5cpR12_BbjRTATqrlQWUco7ZOCzxyz8Z8A0UIqtSuRRIe-84VmYPKk7Arg5ED7T9OUJxa9LTEEu8LCg29-r6PvKf-XDhrXKO2CgjNMTVihfN0UI9GgoEPvnAY_wXFPkC8GcxKWeaXroVdCY_U15ZSxVuOzMth)).\nThe safety and efficacy of epcoritamab has not been established for these\ninvestigational uses. Please visit www.clinicaltrials.gov for more\ninformation.\n\nAbout Genmab  \nGenmab is an international biotechnology company dedicated to improving the\nlives of people with cancer and other serious diseases through innovative\nantibody medicines. For over 25 years, its passionate, innovative and\ncollaborative team has advanced a broad range of antibody-based therapeutic\nformats, including bispecific antibodies, antibody-drug conjugates (ADCs),\nimmune-modulating antibodies and other next-generation modalities. Genmab’s\nscience powers eight approved antibody medicines, and the company is advancing\na strong late-stage clinical pipeline, including wholly owned programs, with\nthe goal of delivering transformative medicines to patients. \n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For\nmore information, please visit Genmab.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZUdKcm9W-tqQOjhGsJKhZOxG1yeVcFrNZ48ozdWRDS37dN-RBTEN_rwetk-7skTId9xs2D0xTs5dv414PWJucY2-pfWQiuQK8vPI-LXoaCXhWWP87207c4vOcqheSqtuZTMrbgbRk0IepN8_0sOSUIZQyLZyxyITT65U6K6mXk1QmuvUk4Z4DHMngUZ1oGWoNi0zIOaoEqHmzB-eb9H7nCZZmJOlKPFQlI_KaMe-jag9mZ5n77LnfaSwhglh6RbZ), X\n(https://www.globenewswire.com/Tracker?data=AFwlRIMSgGxa4On-2XOQD6lOdbFc71_hj92JD7h3bH45WzxODmCpKWs4NjKca-e_OvhPAxI0TL178HHdxTe3gdtDXojBVOJa3jec_J1E2tSHGgNSGA5bpg_y8JWZfeOxym2mFV7Q0rG6FKOsjxpez7ZBHOHbrXWqVC_cFjb21x3kb6X6B5UzCVcT18Zyf3NFsW76myEccQdaAT8uq5SDnhEn0wkATsPZcRnBXPs5k2s=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=rzDzV8Aej0HEuzuoUYFKb1EFDnbWk4UjGqA5WPZDaA89roq4K_7l1XGsSsxcMi-SkayMmGF0nduVFp2HQBFAQ73NeBqu_m_3ZeYPNbbdqXb3i9A16XaYKcfg2orzMFKD) and Instagram\n(https://www.globenewswire.com/Tracker?data=XVsNDl5xrp7COCRVFKlwwV-KsQtVpbkupRzfmkmFuogqrZji1EeyfSFspgI3n2Pd1O9BLFsnBiVEUqEkSbcj7lzqSHVw8GSISgA5wSmEw83Rh1Dh3yZo2xDgjIve70tP9FVAT8frnsXRR4iTff4vfQ==). \n\nAbout AbbVie in Oncology\nAbbVie is committed to elevating standards of care and bringing transformative\ntherapies to patients worldwide living with difficult-to-treat cancers. We are\nadvancing a dynamic pipeline of investigational therapies across a range of\ncancer types in both blood cancers and solid tumors. We are focusing on\ncreating targeted medicines that either impede the reproduction of cancer\ncells or enable their elimination. We achieve this through various, targeted\ntreatment modalities and biology interventions, including small molecule\ntherapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based\ntherapeutics, multispecific antibody and novel CAR-T platforms. Our\ndedicated and experienced team joins forces with innovative partners to\naccelerate the delivery of potential breakthrough medicines.\n\nToday, our expansive oncology portfolio is comprised of approved and\ninvestigational treatments for a wide range of blood and solid tumors. We are\nevaluating more than 35 investigational medicines across some of the world's\nmost widespread and debilitating cancers. As we work to have a remarkable\nimpact on people's lives, we are committed to exploring solutions to help\npatients obtain access to our cancer medicines. For more information, please\nvisit us at http://www.abbvie.com/oncology.\n\nAbout AbbVie\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on\nLinkedIn,\n(https://www.globenewswire.com/Tracker?data=ZUdKcm9W-tqQOjhGsJKhZJ7SlbEG4U_Kdf8fp4A1HwFcvtcn30KFWnbvQG4VPjkc6yHUX8UVJyzVzFa8YpO_uKarrsXZev24VEvYfU5Yt6s=)\nFacebook\n(https://www.globenewswire.com/Tracker?data=rzDzV8Aej0HEuzuoUYFKbytSaXyqk9_n_DF_xc317SDoHG25KKaSDXTcWu6F-iSvOgGjQzjfhuakhdMEcaPFbzJs52YxDSUjb7Zam3WROJk=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=XVsNDl5xrp7COCRVFKlwwQSZgV0bnbtyPt2ndk9Bw4i6QSOFU_smFV35KtNfANVUv1j2e-gmLSe8RK63sFTZthzWtFJKtrKKtvFpz5akbQU=),\nX\n(https://www.globenewswire.com/Tracker?data=q5XoCzyFQ73bm3WrZZ-03QR6tv5Uaew7hPSBpT0a5q7IeXfmkz8Kb2pa5fbxgc95hlbo5-MoobA9tLXepEhYOQ==)\nand YouTube.\n(https://www.globenewswire.com/Tracker?data=ZGFhN4E2UTzB0yxQULUGigd1UXucgx7ciALi1aYGTcB0g_TSHpOtFpj83ov6HZD4_w8OVjrThFpC7XNBK9m4lGHkpIIMHuKbgj23OSnkwvQ=)\n\n Genmab Contacts:  Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com  AbbVie Contacts: Raquel Powers, Director, Oncology Public Affairs T: +1 847 935 6563; E: raquel.powers@abbvie.com  \n Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com                                           Todd Bosse, Vice President, Investor Relations T: +1 847-936-1182; E: todd.bosse@abbvie.com                        \n\nGenmab Forward-Looking Statements\nThis Company Announcement contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Company Announcement nor to confirm such statements to\nreflect subsequent events or circumstances after the date made or in relation\nto actual results, unless required by law.\n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®),\nHexElect(® )and KYSO™. EPCORE(®), EPKINLY(®), TEPKINLY(®) and their\ndesigns are trademarks of AbbVie Biotechnology Ltd. Dr. Salles has financial\ninterests related to AbbVie and Genmab.\n\nAbbVie Forward-Looking Statements\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n\n(i) Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed\nFebruary\n2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/ \n(ii) Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet].\nTreasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.\n(iii) Leukemia and Lymphoma Society. Diffuse Large B-Cell Lymphoma (DLBCL).\nAccessed February\n2026. https://www.lls.org/research/diffuse-large-b-cell-lymphoma-dlbcl \n(iv) Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med.\n2021;384:842-858. doi: 10.1056/NEJMra2027612.\n(v) Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and\nFollicular Lymphoma (FL) in the United States and Western Europe:\nPopulation-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63.\ndoi: 10.1080/10428194.2021.1975188.\n(vi) Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma:\nResults From the International SCHOLAR-1 Study. Blood.\n2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.\n(vii) Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces\npotent T-cell-mediated killing of malignant B cells in preclinical models and\nprovides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.\nDOI: 10.1016/j.ebiom.2019.102625.\n\nCompany Announcement no. 40\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\nAttachment\n*     05102026_CA40_EPCORE DLBCL-2 (Global)\n(https://ml-eu.globenewswire.com/Resource/Download/127e0d48-de76-45ba-aba2-2422b9c6ecbc)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXF0XkC-20261005","title":"Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma","author":"Globe Newswire","ticker":"ABBV","created":"2026-10-05T18:49:00.394Z","tickers":["ABBV","GMAB"],"exchange":"NYSE","article_body":"Company Announcement\n\nCOPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026\n* EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody\ncombination therapy to demonstrate statistically significant and clinically\nmeaningful improvement in progression-free survival (PFS) in frontline\ndiagnosed diffuse large B-cell lymphoma (DLBCL) patients\n* Based on the topline results, Genmab and AbbVie will engage global\nregulatory authorities\nGenmab A/S\n(https://www.globenewswire.com/Tracker?data=AW_Zl3lIf25cNfe3iJ8zMZWSi_BbFABsZPNhliWJir05MQuPFrgG4te4ZY8qu8lbDcwo4knvO5oH8Xjv5rC5BQ==)\n(Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline\nresults from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment\nduration epcoritamab, a T-cell engaging bispecific antibody administered\nsubcutaneously, in combination with standard of care rituximab,\ncyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone\n(R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse\nlarge B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI)\nscore of 2 to 5. The trial demonstrated a statistically significant and\nclinically meaningful improvement in progression-free survival (PFS) in DLBCL\npatients with an IPI score of 2 to 5. The risk of disease progression or death\nwas reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001). The safety\nprofile of epcoritamab when administered in combination with standard of care\nR-CHOP was generally well tolerated and consistent with the previously\nreported safety profiles of the individual agents (epcoritamab and R-CHOP).\n\n“These topline results of epcoritamab in combination with R-CHOP mark the\nfirst Phase 3 study to demonstrate a statistically significant improvement in\nprogression-free survival in patients with newly diagnosed DLBCL treated with\na bispecific antibody combination and have the potential to reshape the\nfrontline treatment landscape,” said Jan van de Winkel, Ph.D., Chief\nExecutive Officer of Genmab. “While treatment advances have improved\noutcomes for patients with diffuse large B-cell lymphoma, options for newly\ndiagnosed patients remain limited, reinforcing the need for additional\ntherapies that can treat as many patients as possible in the frontline\nsetting.”\n\n“DLBCL is an aggressive disease and the need to advance treatment options is\ncritical. These positive topline results suggest that epcoritamab combined\nwith R-CHOP could offer a potential new standard of care in newly diagnosed\nDLBCL patients,” said Daejin Abidoye, MD, vice president, therapeutic area\nhead, oncology, solid tumor and hematology, AbbVie. “The findings further\nstrengthen our understanding and potential of bispecifics across the lymphoma\ntreatment landscape, as we work to address urgent needs in this patient\npopulation.”\n\n\"As an investigator with firsthand experience in both the landmark trial that\nestablished R-CHOP as a standard of care nearly 25 years ago and EPCORE\nDLBCL-2, it is particularly meaningful to see the potential benefit of\nbispecific antibody therapy in newly diagnosed diffuse large B-cell\nlymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service and\nholder of the Steven A. Greenberg Chair at Memorial Sloan Kettering Cancer\nCenter. “The 51% reduction in the risk of progression or death is clinically\nmeaningful and highly relevant to everyday practice. These results have the\npotential to be practice-changing and could mark an important step forward in\nbringing the opportunity of cure to more patients.”\n\nData will be submitted for presentation at a future medical meeting. Genmab\nand AbbVie will engage global regulatory authorities to determine next steps.\nEpcoritamab plus R-CHOP is an investigational combination not approved by\nregulatory authorities.\n\nAbout the EPCORE(®) DLBCL-2 Trial \nEPCORE DLBCL-2 (NCT05578976\n(https://www.globenewswire.com/Tracker?data=fg7FxrXGTAGQushK-9dazm9KG23BceQnBEROsaliGfdWVkaDk_3jHfDf72gxFa8RXZGzKUHcyWxFRQtaTG19BLImWFfsY2aWNm0Vmq0bBOV5EwTKNb9xu7Tg3u4I_Ol2Jk8OsjadoesmoFtYZnk7Zca-gzPL8x_5p-l_nvooBrlwY5F81NzQzCwnNC5XxHm5A1oL_ZCaw6M2z98YUpTEq0nkrhBhCdjA9Fxg5EQrLXKKepIRoaP5BgbDLiHMZz7q-rvqcW-ncvCDKKtJJMdX4LOPKhjNUhbBerrH--K4-w1cUGPwxy9PUjwyO7D6aeqfy5EqBG_-X5hPunsY6cXXoE2OFnkEYBn-iOYlX7_1Qd6daoso6cOm_rHR4eYxgxMyr3R0IG4fvSAbJHomxk-ieQ4ahsVMTFso6_dfE5egg8BbqwoXuPb5DKngXxEnUqBF27pcFeixkwnbKopyatT04FfN7asbYXirYWKEwNGixlAAHJ4O0F4vdwsco4bGD1uebmdUmSGOWXidnizzi1U_hYGAFzlLfTbXVJXJ1CuW1zxr87Wl3t7C-lfNMhRjYoS-nvWL77ZbQHElefPJjXO7u62oPdLrTKvq-GeW-YeqhAk31O_ePyraEIdO1Zgw5AgLFVEaEplNARqpDrP3EZvhXg==))\nis a global Phase 3 open label, multi-center, randomized trial to evaluate the\nefficacy of fixed duration, subcutaneous epcoritamab (GEN3013,\nDuoBody(®)-CD3xCD20) and standard of care rituximab, cyclophosphamide,\ndoxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) compared to\nR-CHOP alone in patients with newly diagnosed large B-cell lymphoma (DLBCL).\nThe trial enrolled subjects with an International Prognostic Index (IPI) score\nof 2 to 5, including patients with diffuse large B-cell lymphoma, not\notherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC\nand BCL2 and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B),\nT-cell/histiocyte-rich large B-Cell lymphoma (TCHR LBLC), and Epstein-Barr\nVirus-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The primary\nendpoint is PFS in participants with an International Prognostic Index (IPI)\nof 3-5 and the key secondary endpoint is PFS in total participants (IPI score\nof 2-5). The risk of disease progression or death for the primary endpoint\npopulation was reduced by 51% (HR 0.49 [95% CI 0.35, 0.69]; p-value < 0.0001).\nPatients were randomized 2:1 to receive a fixed-duration regimen of\nepcoritamab plus R-CHOP for six cycles followed by epcoritamab alone for two\ncycles, or R-CHOP for six cycles followed by rituximab for two cycles. The\ntrial started on February 8, 2023, and is ongoing.\n\nMore information on this trial can be found at\nhttps://clinicaltrials.gov/study/NCT05578976 (NCT: NCT05578976).\n\nAbout Diffuse Large B-Cell Lymphoma\nDiffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of\nnon-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30\npercent of all NHL cases.(i)(,)(ii) In the U.S., there are approximately\n25,000 new cases of DLBCL diagnosed each year.(iii) DLBCL can arise in lymph\nnodes as well as in organs outside of the lymphatic system, occurs more\ncommonly in the elderly and is slightly more prevalent in men.(iv)(,)(v) DLBCL\nis a fast-growing type of NHL, a cancer that develops in the lymphatic system\nand affects B-cell lymphocytes, a type of white blood cell. For many people\nliving with DLBCL, their cancer either relapses, which means it may return\nafter treatment, or becomes refractory, meaning it does not respond to\ntreatment. Although new therapies have become available, treatment management\ncan remain a challenge.(iv)(,)(vi)\n\nAbout Epcoritamab \nEpcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary\nDuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3\ntechnology is designed to direct cytotoxic T cells selectively to elicit an\nimmune response toward target cell types. Epcoritamab is designed to\nsimultaneously bind to CD3 on T cells and CD20 on B cells and induces\nT-cell-mediated killing of CD20+ cells.(vii)\n\nEpcoritamab (approved under the brand name EPKINLY(®) in the U.S. and Japan,\nand TEPKINLY(®) in the EU) has received regulatory approval in certain\nlymphoma indications in more than 65 countries. Where approved, epcoritamab is\na readily accessible therapy. Epcoritamab is being co-developed by Genmab and\nAbbVie as part of the companies' oncology collaboration. The companies share\ncommercial responsibilities in the U.S. and Japan, with AbbVie responsible for\nfurther global commercialization. Both companies will pursue additional\ninternational regulatory approvals for the relapsed or refractory (R/R)\nfollicular lymphoma (FL) indication and additional approvals for the R/R\ndiffuse large B-cell lymphoma (DLBCL) indication. \n\nGenmab and AbbVie continue to evaluate the use of epcoritamab as a\nmonotherapy, and in combination, across lines of therapy in a range of\nhematologic malignancies. This includes a trial evaluating epcoritamab in\ncombination with lenalidomide and rituximab (R(2)) compared to\nchemoimmunotherapy in patients with previously untreated FL (NCT06191744\n(https://www.globenewswire.com/Tracker?data=fg7FxrXGTAGQushK-9dazmobqaLl-UqO2MdV9cKJ9ipMYRN9vINLeOASahrbnVt5_AMVaEpdyFf_Tf6Hr6o_j1GmATokaqHcwuETgd3cpG1m7yhcqcHxHFNTIqUNA__AD4fkb-2vWrSCFWcwWa2YFukUnrPJ_PPZjFxxGDRjkNdSnk_pAA7JLhhyNWRrYyLRFjOacgRAPsk5Ffta0hJ6qHXeN6BYSVDijvHaN_bqhY5o9ENXEqbZsh7tHUZU1jqSW4TBOlq1WxWCRyJ3Wa2UTUYfaJH-kBc36yaoW-cd18CT5xbN6RzCoMgGQvcun0OW4U_cQJkn_-VRwWJwcsUL6FidReum-3W5BaIE4QutTubWsoQ8eQ-fOdfeC-deIGw_EqREP4R1ocbPLDyd5xrArnB_xIIN-rHwcWt5cpR12_BbjRTATqrlQWUco7ZOCzxyz8Z8A0UIqtSuRRIe-84VmYPKk7Arg5ED7T9OUJxa9LTEEu8LCg29-r6PvKf-XDhrXKO2CgjNMTVihfN0UI9GgoEPvnAY_wXFPkC8GcxKWeaXroVdCY_U15ZSxVuOzMth)).\nThe safety and efficacy of epcoritamab has not been established for these\ninvestigational uses. Please visit www.clinicaltrials.gov for more\ninformation.\n\nAbout Genmab  \nGenmab is an international biotechnology company dedicated to improving the\nlives of people with cancer and other serious diseases through innovative\nantibody medicines. For over 25 years, its passionate, innovative and\ncollaborative team has advanced a broad range of antibody-based therapeutic\nformats, including bispecific antibodies, antibody-drug conjugates (ADCs),\nimmune-modulating antibodies and other next-generation modalities. Genmab’s\nscience powers eight approved antibody medicines, and the company is advancing\na strong late-stage clinical pipeline, including wholly owned programs, with\nthe goal of delivering transformative medicines to patients. \n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For\nmore information, please visit Genmab.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZUdKcm9W-tqQOjhGsJKhZOxG1yeVcFrNZ48ozdWRDS37dN-RBTEN_rwetk-7skTId9xs2D0xTs5dv414PWJucY2-pfWQiuQK8vPI-LXoaCXhWWP87207c4vOcqheSqtuZTMrbgbRk0IepN8_0sOSUIZQyLZyxyITT65U6K6mXk1QmuvUk4Z4DHMngUZ1oGWoNi0zIOaoEqHmzB-eb9H7nCZZmJOlKPFQlI_KaMe-jag9mZ5n77LnfaSwhglh6RbZ), X\n(https://www.globenewswire.com/Tracker?data=AFwlRIMSgGxa4On-2XOQD6lOdbFc71_hj92JD7h3bH45WzxODmCpKWs4NjKca-e_OvhPAxI0TL178HHdxTe3gdtDXojBVOJa3jec_J1E2tSHGgNSGA5bpg_y8JWZfeOxym2mFV7Q0rG6FKOsjxpez7ZBHOHbrXWqVC_cFjb21x3kb6X6B5UzCVcT18Zyf3NFsW76myEccQdaAT8uq5SDnhEn0wkATsPZcRnBXPs5k2s=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=rzDzV8Aej0HEuzuoUYFKb1EFDnbWk4UjGqA5WPZDaA89roq4K_7l1XGsSsxcMi-SkayMmGF0nduVFp2HQBFAQ73NeBqu_m_3ZeYPNbbdqXb3i9A16XaYKcfg2orzMFKD) and Instagram\n(https://www.globenewswire.com/Tracker?data=XVsNDl5xrp7COCRVFKlwwV-KsQtVpbkupRzfmkmFuogqrZji1EeyfSFspgI3n2Pd1O9BLFsnBiVEUqEkSbcj7lzqSHVw8GSISgA5wSmEw83Rh1Dh3yZo2xDgjIve70tP9FVAT8frnsXRR4iTff4vfQ==). \n\nAbout AbbVie in Oncology\nAbbVie is committed to elevating standards of care and bringing transformative\ntherapies to patients worldwide living with difficult-to-treat cancers. We are\nadvancing a dynamic pipeline of investigational therapies across a range of\ncancer types in both blood cancers and solid tumors. We are focusing on\ncreating targeted medicines that either impede the reproduction of cancer\ncells or enable their elimination. We achieve this through various, targeted\ntreatment modalities and biology interventions, including small molecule\ntherapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based\ntherapeutics, multispecific antibody and novel CAR-T platforms. Our\ndedicated and experienced team joins forces with innovative partners to\naccelerate the delivery of potential breakthrough medicines.\n\nToday, our expansive oncology portfolio is comprised of approved and\ninvestigational treatments for a wide range of blood and solid tumors. We are\nevaluating more than 35 investigational medicines across some of the world's\nmost widespread and debilitating cancers. As we work to have a remarkable\nimpact on people's lives, we are committed to exploring solutions to help\npatients obtain access to our cancer medicines. For more information, please\nvisit us at http://www.abbvie.com/oncology.\n\nAbout AbbVie\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on\nLinkedIn,\n(https://www.globenewswire.com/Tracker?data=ZUdKcm9W-tqQOjhGsJKhZJ7SlbEG4U_Kdf8fp4A1HwFcvtcn30KFWnbvQG4VPjkc6yHUX8UVJyzVzFa8YpO_uKarrsXZev24VEvYfU5Yt6s=)\nFacebook\n(https://www.globenewswire.com/Tracker?data=rzDzV8Aej0HEuzuoUYFKbytSaXyqk9_n_DF_xc317SDoHG25KKaSDXTcWu6F-iSvOgGjQzjfhuakhdMEcaPFbzJs52YxDSUjb7Zam3WROJk=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=XVsNDl5xrp7COCRVFKlwwQSZgV0bnbtyPt2ndk9Bw4i6QSOFU_smFV35KtNfANVUv1j2e-gmLSe8RK63sFTZthzWtFJKtrKKtvFpz5akbQU=),\nX\n(https://www.globenewswire.com/Tracker?data=q5XoCzyFQ73bm3WrZZ-03QR6tv5Uaew7hPSBpT0a5q7IeXfmkz8Kb2pa5fbxgc95hlbo5-MoobA9tLXepEhYOQ==)\nand YouTube.\n(https://www.globenewswire.com/Tracker?data=ZGFhN4E2UTzB0yxQULUGigd1UXucgx7ciALi1aYGTcB0g_TSHpOtFpj83ov6HZD4_w8OVjrThFpC7XNBK9m4lGHkpIIMHuKbgj23OSnkwvQ=)\n\n Genmab Contacts:  Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com  AbbVie Contacts: Raquel Powers, Director, Oncology Public Affairs T: +1 847 935 6563; E: raquel.powers@abbvie.com  \n Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com                                           Todd Bosse, Vice President, Investor Relations T: +1 847-936-1182; E: todd.bosse@abbvie.com                        \n\nGenmab Forward-Looking Statements\nThis Company Announcement contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Company Announcement nor to confirm such statements to\nreflect subsequent events or circumstances after the date made or in relation\nto actual results, unless required by law.\n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®),\nHexElect(® )and KYSO™. EPCORE(®), EPKINLY(®), TEPKINLY(®) and their\ndesigns are trademarks of AbbVie Biotechnology Ltd. Dr. Salles has financial\ninterests related to AbbVie and Genmab.\n\nAbbVie Forward-Looking Statements\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n\n(i) Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed\nFebruary\n2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/ \n(ii) Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet].\nTreasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.\n(iii) Leukemia and Lymphoma Society. Diffuse Large B-Cell Lymphoma (DLBCL).\nAccessed February\n2026. https://www.lls.org/research/diffuse-large-b-cell-lymphoma-dlbcl \n(iv) Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med.\n2021;384:842-858. doi: 10.1056/NEJMra2027612.\n(v) Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and\nFollicular Lymphoma (FL) in the United States and Western Europe:\nPopulation-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63.\ndoi: 10.1080/10428194.2021.1975188.\n(vi) Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma:\nResults From the International SCHOLAR-1 Study. Blood.\n2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.\n(vii) Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces\npotent T-cell-mediated killing of malignant B cells in preclinical models and\nprovides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.\nDOI: 10.1016/j.ebiom.2019.102625.\n\nCompany Announcement no. 40\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\nAttachment\n*     05102026_CA40_EPCORE DLBCL-2 (Global)\n(https://ml-eu.globenewswire.com/Resource/Download/127e0d48-de76-45ba-aba2-2422b9c6ecbc)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T18:49:00.441338174Z","server_sent_at_ms":1791226140441},"received_at":"2026-10-05T18:49:00.495Z","source_url":null},"analysis":{"id":"149491","press_release_id":"160940","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["epcoritamab plus R-CHOP remains investigational in the frontline setting; regulatory submission and approval outcomes are uncertain","full data not yet presented or peer-reviewed"],"eventType":"clinical_trial","narrative":"AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.\n\nThe trial met its primary endpoint, cutting the risk of disease progression or death by 51% (HR 0.49; p<0.0001) with a safety profile consistent with the individual agents.\n\nThe companies will engage global regulatory authorities on next steps; epcoritamab plus R-CHOP is not yet approved in the frontline setting, but the data could support a new standard of care and expand the EPKINLY label.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First Phase 3 bispecific win in frontline DLBCL positions EPKINLY for a major label expansion and strengthens AbbVie's hematology franchise."},"keyFigures":{"drugName":"epcoritamab (EPKINLY/TEPKINLY)","phaseOfTrial":"Phase 3","customDimensions":{"nct":"NCT05578976","trial":"EPCORE DLBCL-2","p_value":"<0.0001","hazard_ratio":0.49,"pfs_risk_reduction":"51%"}},"quotedText":"These positive topline results suggest that epcoritamab combined with R-CHOP could offer a potential new standard of care in newly diagnosed DLBCL patients","namedEntities":{"people":[{"name":"Jan van de Winkel","role":"CEO, Genmab"},{"name":"Daejin Abidoye","role":"VP, therapeutic area head, oncology, AbbVie"},{"name":"Gilles Salles","role":"Chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center; trial investigator"}],"products":["epcoritamab","EPKINLY","TEPKINLY","R-CHOP","DuoBody-CD3xCD20"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer; co-developer"},{"name":"Genmab A/S","ticker":"GMAB","relationship":"partner"},{"name":"Memorial Sloan Kettering Cancer Center","relationship":"investigator site"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Positive Phase 3 topline for epcoritamab plus R-CHOP in frontline DLBCL, with a 51% reduction in risk of progression or death and plans to engage regulators. A meaningful pipeline catalyst for AbbVie, though not an approval and epcoritamab is one asset within a large portfolio."},"tickerRelevance":{"others":[{"ticker":"GMAB","relevance":"partner; co-developer of epcoritamab"}],"primary":"ABBV"},"globalImportance":55,"audienceRelevance":60,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"positive Phase 3 topline, frontline indication","householdBrandBoost":true,"pipelineMateriality":"one asset within AbbVie's large oncology portfolio"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.\n\nThe trial met its primary endpoint, cutting the risk of disease progression or death by 51% (HR 0.49; p<0.0001) with a safety profile consistent with the individual agents.\n\nThe companies will engage global regulatory authorities on next steps; epcoritamab plus R-CHOP is not yet approved in the frontline setting, but the data could support a new standard of care and expand the EPKINLY label.","key_figures":{"drugName":"epcoritamab (EPKINLY/TEPKINLY)","phaseOfTrial":"Phase 3","customDimensions":{"nct":"NCT05578976","trial":"EPCORE DLBCL-2","p_value":"<0.0001","hazard_ratio":0.49,"pfs_risk_reduction":"51%"}},"named_entities":{"people":[{"name":"Jan van de Winkel","role":"CEO, Genmab"},{"name":"Daejin Abidoye","role":"VP, therapeutic area head, oncology, AbbVie"},{"name":"Gilles Salles","role":"Chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center; trial investigator"}],"products":["epcoritamab","EPKINLY","TEPKINLY","R-CHOP","DuoBody-CD3xCD20"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer; co-developer"},{"name":"Genmab A/S","ticker":"GMAB","relationship":"partner"},{"name":"Memorial Sloan Kettering Cancer Center","relationship":"investigator site"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T18:49:06.751Z","global_importance":55,"audience_relevance":60,"importance_components":{"tickerTier":"mega-cap","eventGravity":"positive Phase 3 topline, frontline indication","householdBrandBoost":true,"pipelineMateriality":"one asset within AbbVie's large oncology portfolio"}},"durationMs":6243,"modelName":"glm-5.3-flashx"}}